QLGN Annual CFF
-$550.00 K
-$3.46 M-118.90%
31 December 2023
Summary:
As of January 19, 2025, QLGN annual cash flow from financing activities is -$550.00 thousand, with the most recent change of -$3.46 million (-118.90%) on December 31, 2023. During the last 3 years, it has fallen by -$34.60 million (-101.62%). QLGN annual CFF is now -101.62% below its all-time high of $34.05 million, reached on December 1, 2020.QLGN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
QLGN Quarterly CFF
$3.32 M
+$2.17 M+188.63%
30 September 2024
Summary:
As of January 19, 2025, QLGN quarterly cash flow from financing activities is $3.32 million, with the most recent change of +$2.17 million (+188.63%) on September 30, 2024. Over the past year, it has increased by +$2.84 million (+598.80%). QLGN quarterly CFF is now -80.23% below its all-time high of $16.79 million, reached on September 30, 2020.QLGN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
QLGN TTM CFF
$4.83 M
+$3.76 M+349.70%
30 September 2024
Summary:
As of January 19, 2025, QLGN TTM cash flow from financing activities is $4.83 million, with the most recent change of +$3.76 million (+349.70%) on September 30, 2024. Over the past year, it has increased by +$4.91 million (+6545.73%). QLGN TTM CFF is now -77.75% below its all-time high of $21.72 million, reached on March 31, 2021.QLGN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
QLGN Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -118.9% | +598.8% | +6545.7% |
| 3 y3 years | -101.6% | +100.0% | +66.3% |
| 5 y5 years | -433.1% | +887.7% | +2671.4% |
QLGN Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -106.5% | at low | -59.3% | +854.4% | -42.7% | +979.0% |
| 5 y | 5-year | -101.6% | at low | -80.2% | +854.4% | -77.8% | +979.0% |
| alltime | all time | -101.6% | at low | -80.2% | +854.4% | -77.8% | +979.0% |
Qualigen Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.32 M(+188.6%) | $4.83 M(+349.7%) |
| June 2024 | - | $1.15 M(+142.1%) | $1.07 M(-1533.3%) |
| Mar 2024 | - | $475.00 K(-531.8%) | -$75.00 K(-86.4%) |
| Dec 2023 | -$550.00 K(-118.9%) | -$110.00 K(-75.0%) | -$550.00 K(-122.3%) |
| Sept 2023 | - | -$440.00 K(<-9900.0%) | $2.46 M(-15.3%) |
| June 2023 | - | $0.00(0.0%) | $2.91 M(0.0%) |
| Mar 2023 | - | $0.00(-100.0%) | $2.91 M(-0.1%) |
| Dec 2022 | $2.91 M | $2.90 M(>+9900.0%) | $2.91 M(-64.3%) |
| Sept 2022 | - | $3300.00(>+9900.0%) | $8.16 M(-1.5%) |
| June 2022 | - | $0.00(-100.0%) | $8.28 M(-0.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $3900.00(-100.0%) | $8.32 M(-1.4%) |
| Dec 2021 | $8.43 M(-75.2%) | $8.15 M(+6197.4%) | $8.43 M(+2860.2%) |
| Sept 2021 | - | $129.40 K(+279.5%) | $284.90 K(-98.3%) |
| June 2021 | - | $34.10 K(-71.9%) | $16.94 M(-22.0%) |
| Mar 2021 | - | $121.40 K(-99.3%) | $21.72 M(+0.6%) |
| Dec 2020 | $34.05 M(>+9900.0%) | - | - |
| Sept 2020 | - | $16.79 M(+248.5%) | $21.60 M(+391.5%) |
| June 2020 | - | $4.82 M(-1243.0%) | $4.40 M(-2437.8%) |
| Mar 2020 | $165.10 K | - | - |
| Sept 2019 | - | -$421.40 K(-280.5%) | -$188.00 K(-180.5%) |
| June 2019 | - | $233.40 K | $233.40 K |
FAQ
- What is Qualigen Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Qualigen Therapeutics?
- What is Qualigen Therapeutics annual CFF year-on-year change?
- What is Qualigen Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Qualigen Therapeutics?
- What is Qualigen Therapeutics quarterly CFF year-on-year change?
- What is Qualigen Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Qualigen Therapeutics?
- What is Qualigen Therapeutics TTM CFF year-on-year change?
What is Qualigen Therapeutics annual cash flow from financing activities?
The current annual CFF of QLGN is -$550.00 K
What is the all time high annual CFF for Qualigen Therapeutics?
Qualigen Therapeutics all-time high annual cash flow from financing activities is $34.05 M
What is Qualigen Therapeutics annual CFF year-on-year change?
Over the past year, QLGN annual cash flow from financing activities has changed by -$3.46 M (-118.90%)
What is Qualigen Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of QLGN is $3.32 M
What is the all time high quarterly CFF for Qualigen Therapeutics?
Qualigen Therapeutics all-time high quarterly cash flow from financing activities is $16.79 M
What is Qualigen Therapeutics quarterly CFF year-on-year change?
Over the past year, QLGN quarterly cash flow from financing activities has changed by +$2.84 M (+598.80%)
What is Qualigen Therapeutics TTM cash flow from financing activities?
The current TTM CFF of QLGN is $4.83 M
What is the all time high TTM CFF for Qualigen Therapeutics?
Qualigen Therapeutics all-time high TTM cash flow from financing activities is $21.72 M
What is Qualigen Therapeutics TTM CFF year-on-year change?
Over the past year, QLGN TTM cash flow from financing activities has changed by +$4.91 M (+6545.73%)